Metropolis Healthcare announced robust financial results for the second quarter and first half of FY27. Revenue grew by 16% year-on-year for Q2 and 16.2% for H1, surpassing guidance. EBITDA margins expanded by 190 basis points to 26.2% in H1. The company also declared an interim dividend of INR1 per share, reflecting confidence in its sustained growth trajectory and profitability.
Metropolis Healthcare Q2 and H1 FY27 Earnings Performance
Metropolis Healthcare Limited has reported strong financial performance for the second quarter (Q2) and the first half (H1) of FY27. The company announced a revenue growth of 16% for Q2 and 16.2% for H1 FY27, exceeding its previously stated guidance of 12% to 13%. This growth was achieved organically across B2C and B2B channels and all geographic segments, including Tier 3 and rural markets which showed approximately 20% revenue growth.
Margin Expansion and Profitability
A key highlight of the results was the significant expansion in profitability. EBITDA margins grew by 190 basis points year-on-year, reaching 26.2% for H1 FY27. This expansion was attributed to volume-led operating leverage, disciplined cost management, and productivity improvements. Profit After Tax (PAT) for Q2 FY27 stood at INR75 crores, marking a 43% year-on-year growth with a PAT margin of 15.2%, the highest post-COVID period. The company also highlighted a strong cash position with liquid investments of INR348 crores as of September 30, 2026.
Dividend Declaration and Future Outlook
In line with its robust performance, Metropolis Healthcare announced an interim dividend of INR1 per share. Management expressed confidence in continuing the growth and margin trajectory for the rest of the year, driven by strategic priorities including science and technology investments, automation, AI deployment, and a disciplined inorganic strategy. The company also noted a potential price revision in early 2027, to be implemented cautiously and data-driven.
Strategic Initiatives
The company emphasized its focus on building a strong ecosystem around its core diagnostics business, including exploring new models in preventive health care and piloting ancillary services. Investments in technology, such as a new CRM platform and enhanced SLIMS integration, are aimed at improving customer engagement, operational efficiency, and data-driven decision-making. The acquisition strategy continues to focus on value creation with a target IRR of around 20%.
Source: BSE
